Therese Törngren

发表

COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration

Peter Kraft, Mads Thomassen, Daniel J. Park, 2013, Breast Cancer Research.

NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics

L. Saal, N. Hayward, H. Olsson, 2017, Molecular oncology.

Molecular and genetic diversity in the metastatic process of melanoma

L. Saal, H. Olsson, M. Lauss, 2014, The Journal of pathology.

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

M. Ringnér, M. Lauss, M. Donia, 2017, Nature Communications.

Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes

U. Jensen, M. Larsen, M. Thomassen, 2023, Scientific reports.

Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants: Application of a points‐based ACMG/AMP approach

L. Andrews, P. Møller, A. Spurdle, 2022, Human mutation.

Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.

Jaana M. Hartikainen, M. Beckmann, P. Fasching, 2021, The New England journal of medicine.

Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer

L. Saal, Å. Borg, S. Gruvberger-Saal, 2015, PloS one.

Androgen receptor htSNPs in relation to androgen levels and OC use in young women from high-risk breast cancer families.

H. Jernström, M. Henningson, H. Olsson, 2011, Molecular genetics and metabolism.

Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic

L. Saal, Å. Borg, N. Loman, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma.

Frida Rosengren, Helena Cirenajwis, Martin Lauss, 2016, Cancer research.

Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy

Johan Staaf, Frida Rosengren, Markus Ringnér, 2015, Oncotarget.

Genome-wide RNAi Screen Identifies Cohesin Genes as Modifiers of Renewal and Differentiation in Human HSCs.

B. Nilsson, Å. Borg, S. Soneji, 2016, Cell reports.

Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study

A. Børresen-Dale, C. Begg, Å. Borg, 2010, Human mutation.

Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom‐in array comparative genomic hybridization (aCGH)

Å. Borg, J. Staaf, M. Nilbert, 2008, Human mutation.

Gene‐panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication

F. Couch, Å. Borg, H. Nevanlinna, 2018, Clinical genetics.

Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing

Å. Borg, J. Carlson, T. Petta, 2021, Cancers.

Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study

C. Begg, Å. Borg, L. Bernstein, 2010, Cancer Causes & Control.

L. Saal, Å. Borg, S. Gruvberger-Saal, 2015, Oncotarget.

Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells

A. Børglum, Likun Du, Q. Pan-Hammarström, 2015, Proceedings of the National Academy of Sciences.

Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma

M. Ringnér, Å. Borg, H. Olsson, 2012, Clinical Cancer Research.

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

B. Bonanni, M. Urioste, J. Benítez, 2020, Cancers.

Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility

J. Benítez, Å. Borg, R. Schmutzler, 2017, Genetics in Medicine.

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

Katherine M. Tucker, Sebastian A. Wagner, Kelly J. Sullivan, 2019, Human Mutation.

Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer

A. Lindblom, M. Stenmark-Askmalm, B. Arver, 2023, BMC Cancer.

Expanding the genotype–phenotype spectrum in hereditary colorectal cancer by gene panel testing

Å. Borg, M. Nilbert, A. Kvist, 2016, Familial Cancer.

IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer

H. Jernström, M. Henningson, H. Olsson, 2011, Familial Cancer.

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

C. Begg, Å. Borg, L. Bernstein, 2010, Breast Cancer Research and Treatment.

Genetic Testing and Clinical Management Practices for Variants inNon-BRCA1/2 Breast (and Breast/Ovarian)Cancer Susceptibility Genes: An International Survey by the Evidence-BasedNetwork for the Interpretation of Germline Mutant Alleles (ENIGMA) ClinicalWorking Group

O. Olopade, C. Lázaro, S. Manoukian, 2019 .

Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group.

F. Couch, O. Olopade, R. Eeles, 2018, JCO precision oncology.